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Essentials
• Venous thromboembolism (VTE) recurrence leads to
decreased clot elastic modulus in plasma.
• Recurrent VTE is not linked to changes in clot struc-
ture, fiber radius, or factor XIII activity.
• Other plasma components may play a role in VTE
recurrence.
• Prospective studies should resolve if clot stiffness can be
used as predictor for recurrent VTE.
Summary. Background: Venous thromboembolism (VTE)
is associated with a high risk of recurrent events after
withdrawal of anticoagulation. Objectives: To determine
the difference in plasma clot mechanical properties
between patients with recurrent VTE (rVTE) and those
with non-recurrent VTE (nrVTE). Methods: We previ-
ously developed a system for determining clot mechanical
properties by use of an in-house magnetic tweezers sys-
tem. This system was used to determine the mechanical
properties of clots made from plasma of 11 patients with
rVTE and 33 with nrVTE. Plasma was mixed with
micrometer-sized beads, and thrombin and calcium were
added to induce clotting; the mixture was then placed in
small capillary tubes, and clotting was allowed to proceed
overnight. Bead displacements upon manipulation with
magnetic forces were analyzed to determine clot elastic
and viscous moduli. Fibrin clot structure was analyzed
with turbidimetry and confocal microscopy. Factor XIII
was measured by pentylamine incorporation into fib-
rin. Results: Clots from rVTE patients showed nearly
two-fold less elastic and less viscous moduli than clots
from nrVTE patients, regardless of male sex, unprovoked
events, family history of VTE, fibrinogen concentration,
or body mass index. No differences were observed in clot
structure, fibrinolysis rates, or FXIII levels. Conclusion:
Using magnetic tweezers for the first time in patient sam-
ples, we found that plasma clots from rVTE patients
showed a reduced elastic modulus and a reduced viscous
modulus as compared with clots from nrVTE patients.
These data indicate a possible role for fibrin clot vis-
coelastic properties in determining VTE recurrence.
Keywords: fibrin; mechanics; recurrent event; rheology;
venous thromboembolism.
Introduction
Venous thromboembolism (VTE), which encompasses deep
vein thrombosis (DVT) and pulmonary embolism (PE),
affects 0.1–0.3% of people per year [1,2]. It is divided into
two different categories, i.e. provoked and unprovoked (id-
iopathic); the latter is characterized by the patient having
no history of cancer, surgery requiring general anesthesia,
major trauma, plaster cast or recent hospitalization, includ-
ing for pregnancy or delivery. VTE treatment is aimed at
preventing and predicting recurrence, which may lead to
death, thromboembolic pulmonary hypertension, and post-
thrombotic syndrome [3–5].
Studies in recent years have indicated that fibrin clot
properties constitute a novel risk factor for both DVT
and PE [6]. Clots from these patients have been shown to
have thinner, more highly branched fibers, and are less
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porous and more resistant to lysis than clots from healthy
controls. These clot abnormalities persist or worsen in
patients with post-thrombotic syndrome [7]. Furthermore,
circulating fibrinogen levels have also been shown to
increase in VTE patients [8]. In addition, increases in clot
lysis time have been shown to be weakly associated with
VTE recurrence in women but not in men [9]. Mechani-
cally, clots made from PE patient plasma have been
shown to develop viscoelastic properties at an accelerated
rate as compared with clots made from DVT patients,
although, interestingly, the final mechanical properties for
these two patient groups were similar [10].
In this study, we used magnetic microrheology for the
first time to determine the viscoelastic properties of plasma
clots from patients with recurrent VTE (rVTE) and non-
recurrent VTE (nrVTE). Magnetic microrheology is advan-
tageous in that it is much more sensitive to small changes
than traditional rheology experiments, and it requires only
low plasma volumes of 30 lL per patient. Previous studies
using other methods for the analysis of clot mechanical
properties required higher patient plasma volumes, ranging
from 100 lL [10] to as much as 4.5 mL [11]. We found sig-
nificant differences in plasma clot viscoelastic properties
between patients with rVTE and patients with nrVTE.
These data suggest that this technique may be a useful
diagnostic tool for determining patient clot elastic modulus
as a novel risk factor for VTE recurrence.
Materials and methods
VTE patients
Forty-four patients were recruited to the study: 33
patients who had experienced one first-ever-documented
VTE episode, and 11 patients who had experienced two
or more VTE episodes. All patients were aged between
18 years and 63 years (median, 34 years). Patients were
eligible if at least 3 months had elapsed from their last
VTE episode. The diagnosis of DVT of the lower or
upper limb was established by a positive finding on color
duplex sonography (visualization of an intraluminal
thrombus in the calf, popliteal, femoral, or iliac vein).
The diagnosis of PE was based on the presence of typical
symptoms and positive results on high-resolution spiral
computed tomography. An unprovoked (idiopathic) VTE
episode was defined as the patient having no history of
cancer, surgery requiring general anesthesia, major
trauma, plaster cast or hospitalization in the last month,
or pregnancy or delivery in the last 3 months. A family
history of VTE was defined as the patient having at least
one first-degree relative with VTE. The exclusion criteria
were: acute infection, known malignancy, acute coronary
syndromes or stroke within the preceding 6 months, indi-
cation for long-term anticoagulation for reasons than
VTE, end-stage kidney disease, inherited and acquired
thrombophilias, including factor V Leiden mutation and
prothrombin G20210A, deficiencies in natural anticoagu-
lants, i.e. antithrombin, protein C, or protein S, and refu-
sal to provide consent. The Jagiellonian University
Ethical Committee approved the study, and participants
provided informed consent in accordance with the Decla-
ration of Helsinki.
Blood collection and analysis
Blood samples were taken from the antecubital vein at
least 3 months after the patient’s last VTE, between
8 a.m. and 11 a.m. For patients taking low molecular
weight heparin, blood was collected 20–24 h after their
last injection. For patients receiving vitamin K antago-
nists or rivaroxaban, blood was collected at least 24 h
after their last drug intake. All other samples were col-
lected at least 3–5 months after the last anticoagulant
withdrawal. Smokers were asked to refrain from smoking
for 2 h prior to blood collection. Blood samples (9 : 1 v/v
3.2% trisodium citrate) were centrifuged at 2000 9 g for
10 min, and the supernatant was aliquoted and stored at
 80 °C for analysis. Routine laboratory assays were used
to determine basic biochemical parameters. The fibrinogen
concentration was determined with the Clauss method.
Fibrinogen was purified from 16 VTE patients (five
with rVTE; 11 with nrVTE) by the use of IF1 (fibrinogen
mAb; Kamiya Biomedical Company, Seattle, WA, USA)
affinity chromatography as described previously [12].
Purified fibrinogen was subjected to 10% SDS-PAGE to
confirm purity and the absence of protein degradation.
Isolated fibrinogen was pooled to obtain a concentration
of 1.0 g L1. Finally, it was suspended in Tris-buffered saline
(0.1 mol L1 Tris-HCl and 0.154 mol L1 NaCl, pH 7.4).
All measurements were performed by researchers who
were blinded to the origin of the samples.
Magnetic microrheology
Viscoelastic properties were measured as previously
described [13,14]. Plasma samples were diluted 1 : 10 (fi-
nal volume) in Tris-buffered saline (TBS) (50 mmol L1
Tris-HCl and 100 mmol L1 NaCl2, pH 7.4) and mixed
with superparamagnetic beads at 1 : 250 (v/v) (4.5 lm in
diameter, Dynabeads M-450 Epoxy; Invitrogen, Paisley,
UK). To induce clotting, an activation mixture of
0.5 U mL1 human a-thrombin (Merck, Millipore,
Watford, UK) and 5 mmol L1 CaCl2 was added to the
plasma and quickly pipette-mixed. Immediately after mix-
ing, the solution was pulled into a capillary tube (CM
Scientific Ltd, Keighley, UK), sealed on both ends with
petroleum jelly, and allowed to clot overnight. For puri-
fied samples, final concentrations of 0.5 mg mL1 fibrino-
gen, 0.5 U mL1 thrombin, and 2.5 mmol L1 CaCl2
were used for all experiments.
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Clot viscoelasticity was measured by suspending the cap-
illary between four electromagnets on top of an inverted
microscope (Olympus IX71, Southend-on-sea, UK). A
long-working-distance 9 40 objective and CCD camera
were used to locate the beads suspended within each clot.
Bead tracking, image analysis and control of the electro-
magnets were performed with custom LABVIEW software
(National Instruments, Newbury, UK). The elastic (Gʹ) and
the viscous (G″) shear modulus were calculated from the
time-dependent compliance (ratio of time-dependent shear
strain or bead displacement to the magnitude of the applied
force), which allows for determination of frequency-depen-
dent moduli. The loss tangent (tand = G″/Gʹ) was calcu-
lated as the ratio between the viscous and elastic moduli.
More viscous materials result in a tand that is > 1. More
elastic materials result in a tand that is < 1. For a com-
pletely viscoelastic material, tand will be equal to 1. The dis-
placement of 10 random beads was measured per sample.
Turbidimetric analysis of fiber radius and internal structure
Average fiber radius and average number of protofibrils
per fiber were determined with turbidimetric measure-
ments as previously described [15], taking into account
that the index of refraction changes as a function of
wavelength, as described by Ferri et al. [16]. Clots were
allowed to form in UV–visible transparent plastic cuvettes
(Eppendorf UVette; Sigma-Aldrich, Dorset, UK) over-
night in a final volume of 100 lL. Plasma was diluted
1 : 6 (final volume) in TBS, and clots were activated with
final concentrations of 0.5 U mL1 human a-thrombin
and 5 mmol L1 CaCl2. Plasma was not available from
two rVTE and three nrVTE patients for these experi-
ments. Purified samples were diluted to final concentra-
tions of 0.5 mg mL1 fibrinogen, and activated with final
concentrations of 0.5 U mL1 human a-thrombin and
2.5 mmol L1 CaCl2. A purified sample was not available
from one rVTE patient for these experiments. The cuvette
was sealed with parafilm to prevent dehydration. After
clot formation, the cuvette was scanned over wavelengths
between 500 < k < 800 nm in a K 35 UV–visible spec-
trophotometer (Perkin-Elmer, Cambridge, UK). Measure-
ments for each patient (plasma or purified) were
performed in triplicate.
Turbidity and fibrinolysis
Clot formation and fibrinolysis were measured in 96-well
plates (Greiner, Stonehouse, UK) with a Powerwave
microplate reader (Bio-Tek, Swindon, UK) as previously
described [17]. Plasma was diluted to a final concentration
of 1 : 6 in TBS. Clot formation for turbidity and fibrinol-
ysis measurements was activated by adding final concen-
trations of 0.1 U mL1 human a-thrombin and
10 mmol L1 CaCl2. For fibrinolysis measurements, tis-
sue-type plasminogen activator was added at a final
concentration of 30 ng mL1. The absorbance (or OD)
was measured at a wavelength of 340 nm every 12 s for
3.5 h at 37 °C. Absorbance for turbidity and fibrinolysis
measurements was determined in duplicate for all plasma
samples. Turbidity profiles were analyzed for maximum
absorbance (maximum OD), lag time, time to maximum
absorbance, and average rate of clot formation. Fibrinol-
ysis was analyzed for average rate of fibrinolysis and time
to half-maximum absorbance (half lysis).
Laser scanning confocal microscopy
Structural analysis of VTE patient plasma clots was per-
formed with laser scanning confocal microscopy. Plasma
was diluted to a final volume of 1 : 4 in TBS, and spiked
with Alexa Fluor 488-labeled fibrinogen at a final concen-
tration of 50 lg mL1. Clotting was initiated by adding
human a-thrombin and CaCl2 at final concentrations of
0.1 U mL1 and 10 mmol L1, respectively. Immediately
following clot initiation, clotting solution was transferred
to a well of an uncoated six-well Ibidi slide (Ibidi GmbH,
Martinsried, Germany), placed in a humidity chamber,
and left to clot for 3 h at room temperature. Images were
taken with a Zeiss LSM880 inverted microscope with a
9 40 oil immersion objective lens (Carl Zeiss Ltd, Cam-
bridge, UK). Three images were taken for each clot, and
Z-stacks (30 slices at 20-lm total distance) were combined
and flattened to show maximum intensity (IMAGEJ; NIH,
Bethesda, MD, USA).
5-(Biotinamido)pentylamine incorporation assay
Measurement of FXIII activation and activity was
performed with a modified 5-(biotinamido)pentylamine
incorporation assay, as previously described [18]. Nunc-
Immuno 96 MicroWell plates (Fisher Scientific, Loughbor-
ough, UK) were coated with 100 lL of 40 lg mL1
FXIII-free fibrinogen for 40 min at room temperature, and
then blocked with 300 lL of 1% (w/v) bovine serum albu-
min (BSA) in TBS for 90 min at 37 °C. Plates were washed
with 4 9 300 lL TBS, and 10 lL of sample, diluted 1 : 5
in TBS, was added to the wells. Ninety microliters of activa-
tion mix (111 lmol L1 dithiothreitol, 0.3 lmol L1
biotinylated pentylamine, 11 mmol L1 CaCl2, and
2.2 U mL1 thrombin) was added, and the reactions were
stopped at 0, 5, 10, 15 and 120 min by addition of 200 lL
of 200 mmol L1 EDTA. Plates were washed with
4 9 300 lL of 0.1% (v/v) Tween 20 in TBS, and 100 lL of
2 lg mL1 streptavidin in 1% (w/v) BSA (in TBS–Tween)
was added for 60 min at 37 °C. Following washes with
4 9 300 lL of TBS–Tween, 100 lL of 1 mg mL1 phos-
phatase substrate (in 1 mol L1 diethanolamine) was added,
and the reaction was stopped by addition of 100 lL of
4 mol L1 NaOH. Absorbance was measured at 405 nm,
with a SpectraMax 190 absorbance microtiter plate reader
(Molecular Devices, Wokingham, UK). The rate of
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pentylamine incorporation over early time points was used
as an indicator of FXIII activation, and the data from the
final time point were used to quantify final FXIII activity.
Statistical analysis
Categorical variables are presented as numbers and per-
centages. Continuous variables are expressed as mean  s-
tandard deviation or median and interquartile range.
Normality was assessed with the Shapiro–Wilk test. Differ-
ences between groups were analyzed by the use of Stu-
dent’s t-test for normally distributed variables and the
Mann–Whitney U-test for non-normally distributed contin-
uous variables. Categorical variables were compared by
use of the chi-square test. All calculations were performed
with STATISTICA Version 12.5 (StatSoft, Tulsa, OK, USA).
Results
Patients with rVTE form clots with a decreased elastic
modulus
The demographic characteristics of the patients, C-reac-
tive protein, fibrinogen, anticoagulation and International
Normalized Ratio are shown in Table 1. The mechanical
properties of plasma clots from patients with rVTE
(n = 11) showed a reduced elastic modulus as compared
with those from patients with nrVTE (n = 33) over all fre-
quencies measured (Fig. 1A). Specific frequency values
corresponding to different shear relaxation modes (0.1, 1
and 10 Hz) were used to study clot mechanical behavior
[19]. These frequencies are shown in Fig. 1C. There were
significant increases in storage modulus (Gʹ) at 0.1 Hz
(1.30 Pa versus 0.54 Pa), 1 Hz (1.43 Pa versus 0.78 Pa)
and 10 Hz (6.49 Pa versus 3.18 Pa) for nrVTE versus
rVTE (Table 2). There was also a significant increase in
loss modulus (G″) over each of these frequencies (0.15 Pa
versus 0.08 Pa at 0.1 Hz, 1.37 Pa versus 0.74 Pa at 1 Hz,
and 4.69 Pa versus 1.43 Pa at 10 Hz; Fig. 1B,D; Table 2).
The loss tangent (tand = G″/Gʹ), which is a measure of
the relative ratio between viscous and elastic properties,
showed no difference at either 0.1, 1 or 10 Hz (Table 2).
Fibrinogen was purified from a subset of these plasma
samples. In contrast to what we found for plasma clots,
we found no difference in viscoelastic properties (Gʹ or G″)
between rVTE samples (n = 6) and nrVTE samples
(n = 11) (Fig. S1).
Table 1 Characteristics of patients with recurrent and non-recurrent venous thomboembolism (VTE)
Variable
VTE patients
(n = 44)
Recurrent VTE
(n = 11)
Non-recurrent
VTE (n = 33) P-value
Age (years), median (25–75% quartile) 34 (32–47) 34 (32–40) 35 (29–48) 0.87
Male sex, n (%) 13 (28.9) 5 (45.5) 8 (23.5) 0.16
Body mass index (kg/m2), mean  SD 27.0  5.4 25.2  5.7 26.8  5.4 0.99
DVT alone, n (%) 15 (34.1) 4 (36.4) 11 (33.3) 0.85
PE alone, n (%) 15 (34.1) 4 (36.4) 11 (33.3) 0.85
Unprovoked VTE, n (%) 25 (55.6) 9 (81.8) 16 (47.1) 0.044
Family history of VTE, n (%) 7 (15.6) 0 7 (20.6) 0.12
Time since the index event (months),
median (25–75% quartile)
12 (8–22) 12 (8–18) 14 (8–24) 0.95
White blood cells (103 lL–1), mean  SD 6.11  1.52 6.0  1.32 6.14  1.59 0.78
Red blood cells (106 lL–1), mean  SD 4.76  0.41 4.81  0.47 4.74  0.39 0.52
Haemoglobin (g dL–1), mean  SD 13.9  1.4 14.2  1.2 13.8  1.5 0.52
Hematocrit (%), mean  SD 41.5  3.3 42.6  3.3 41.2  3.3 0.23
Red cell distribution width (%), mean  SD 13.3  0.9 13.6  1.2 13.2  0.8 0.36
Platelets (103 lL–1), mean  SD 246  65 244  83 246  60 0.96
Glucose (mmol L1), median (25–75% quartile) 5.1 (4.8–5.4) 5.0 (4.7–5.3) 5.1 (4.8–5.6) 0.70
Total cholesterol (mmol L1), mean  SD 5.22  1.20 5.86  1.25 5.01  1.12 0.07
LDL cholesterol (mmol L1), mean  SD 3.44  1.06 4.02  1.05 3.26  1.0 0.038
HDL cholesterol (mmol L1), mean  SD 1.48  0.33 1.48  0.35 1.47  0.32 0.81
Triglycerides (mmol L1), median (25–75% quartile) 1.23 (0.86–1.77) 1.30 (0.97–1.83) 1.21 (0.83–1.68) 0.48
C-reactive protein (mg L–1), median (25–75% quartile) 1.50 (0.84–4.25) 2.37 (1.04–6.38) 1.50 (0.83–2.77) 0.25
D-dimer (ng mL–1), median (25–75% quartile) 247 (171–406) 250 (170–435) 278 (171–384) 0.95
Fibrinogen (g L–1), median (25–75% quartile) 3.11  0.62 3.01  0.61 3.14  0.63 0.61
Vitamin K antagonist, n (%) 19 (43.2) 4 (36.4) 15 (45.5) 0.74
INR, median (25–75% quartile) 1.06 (0.99–1.51) 1.03 (1.00–1.45) 1.07 (0.99–1.61) 0.91
Rivaroxaban, n (%) 4 (9.1) 0 (0) 4 (12.1) 0.56
LMWH, n (%)* 3 (6.8) 2 (18.2) 1 (3.0) 0.14
DVT, deep vein thrombosis; INR, International Normalized Ratio; LMWH, low molecular weight heparin; PE, pulmonary embolism; SD,
standard deviation. P-values were obtained with the v2 test for sex, unprovoked VTE, family history of VTE, vitamin K antagonist, rivaroxa-
ban, and LMWH, and with Student’s t-test for body mass index and fibrinogen. All other P-values were obtained with a Mann–Whitney test.
*For the three samples from patients receiving LMWH, the level of anti factor Xa was determined to be < 0.02 IU mL–1 for each sample.
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Fiber diameter and intrafibrillar structure
No significant differences were found in average fiber
diameter or average number of protofibrils packed per
fibrin fiber between plasma clots made from rVTE sam-
ples and those made from nrVTE samples, as shown in
Fig. 2A,B. Similarly, clots made from purified fibrinogen
showed no significant difference in either average fiber
diameter or average number of protofibrils between rVTE
and nrVTE samples (Fig. 2C,D).
Plasma clot structure, formation, and fibrinolysis
The structure of fully formed clots was studied with laser
scanning confocal microscopy. No significant differences
in clot structure were observed between plasma clots
formed from rVTE samples (Fig. 3A) and those formed
from nrVTE samples (Fig. 3B). Furthermore, there was
no difference in the average number of fibers per 100 lm
between rVTE (52  5) and nrVTE (55  7) plasma sam-
ples (Fig. 3C).
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Fig. 1. Viscoelastic moduli for clots made with platelet-poor plasma from patients with recurrent or non-recurrent venous thromboembolism
(VTE). (A, B) Log–log plots of Gʹ or storage (elastic) modulus (A) and G″ or loss modulus (B) over all measured frequencies. (C, D) Compar-
ison of storage modulus (C) and loss modulus (D) corresponding to specific relaxation modes (0.1, 1 and 10 Hz) showed that, at all frequen-
cies, non-recurrent VTE samples had significantly higher modulus values that recurrent VTE samples. **P < 0.01, ***P < 0.001.
Table 2 Viscoelastic properties of venous thromboembolism (VTE) plasma clots
VTE patients (n = 44) Recurrent VTE (n = 11) Non-recurrent VTE (n = 33) P-value
G0 0.1 Hz (Pa) 0.98 (0.62–0.50) 0.54 (0.43–0.67) 1.30 (0.80–1.81) 0.002
G0 1 Hz (Pa) 1.24 (0.86–1.94) 0.78 (0.57–0.90) 1.43 (1.10–2.04) 0.0015
G0 10 Hz (Pa) 5.29 (3.54–8.50) 3.18 (2.22–4.02) 6.49 (4.53–9.49) 0.0006
G″ 0.1 Hz (Pa) 0.13 (0.08–0.18) 0.08 (0.05–0.09) 0.15 (0.10–0.21) 0.0011
G″ 1 Hz (Pa) 1.16 (0.78–1.67) 0.74 (0.43–0.88) 1.37 (0.94–1.95) 0.0008
G″ 10 Hz (Pa) 3.86 (1.43–7.45) 1.43 (0.63–2.31) 4.69 (2.01–8.75) 0.0043
Tand 0.1 Hz 0.12 (0.10–0.15) 0.13 (0.11–0.18) 0.11 (0.10–0.15) 0.43
Tand 1 Hz 0.90 (0.78–1.02) 0.95 (0.83–1.03) 0.89 (0.77–1.02) 0.53
Tand 10 Hz 0.59 (0.32–1.16) 0.39 (0.28–0.66) 0.64 (0.44–1.21) 0.16
Values are given as median (25–75% quartile). P-values were obtained with the Mann–Whitney test.
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Next, we determined the average change in absorbance
over time in plasma samples from rVTE and nrVTE
patients (Fig. 4A). A significant decrease in maximum
absorbance was observed in samples from rVTE patients
(0.44  0.14 at k = 340 nm) as compared with samples
from nrVTE patients (0.52  0.11) (Fig. 4B). We found
no significant differences in other clot formation proper-
ties observed, including: lag time (183  15 s versus
193  24 s; Fig. 4C), time to maximum absorbance
(101  20 s versus 110  18 s), or average rate of clot-
ting (0.12  0.03 versus 0.12  0.04, ΔOD s–1)
(Table 3). Clots also broke down similarly over time
by fibrinolysis (Fig. 4D). No significant differences were
observed in either time to half-lysis (44  12 min ver-
sus 47  20 min) or average rate of lysis
(0.027  0.010 versus 0.033  0.012, ΔOD s–1) (Fig. 4E,
F; Table 3). Note that all of the above values are
given as rVTE versus nrVTE.
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FXIII activity
We measured FXIII activity for all patient plasma sam-
ples. The FXIII activation rate for rVTE samples
(102%  11% of normal pooled plasma) was not differ-
ent from that for nrVTE samples (107%  12%)
(Fig. S2A). Similarly, the final FXIII activities for rVTE
(102%  5% of normal pooled plasma) and nrVTE
(98  5%) plasma samples were unchanged (Fig. S2B).
Discussion
Rheology is an important tool for studying the vis-
coelastic properties of materials, and has been widely
used to study biological samples and, in particular, fib-
rin clots [20–22]. The majority of rheology experiments
use mechanical bulk rheometers to deform materials to
differing strains [23]. Traditional rheology experiments
can be difficult to use on biological samples, such as
plasma, because they typically require large volumes,
are less sensitive to low viscosities, or are limited to
low frequency ranges. Microrheology allows for a wide
range of frequencies and can be carried out with very
small sample volumes [23]. As a result, microrheology
is ideal for patient analysis when sample volumes can
be limited.
To our knowledge, this is the first study to use a mag-
netic tweezers microrheology system to assess plasma fib-
rin viscoelastic properties in real-life patient samples. We
studied the mechanics of plasma and purified clots made
from patients with rVTE and nrVTE. In plasma samples,
nrVTE patients showed a reduced elastic modulus as
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Fig. 4. Turbidity and lysis for plasma clots from venous thromboembolism (VTE) patients. (A) Turbidity profile for non-recurrent and recur-
rent VTE plasma clots measured at 340 nm. The line represents the mean, and the shaded area represents the standard deviation. (B) Maxi-
mum absorbance showed a significant difference between non-recurrent and recurrent VTE samples. (C) Lag time or the amount of time to
measurable absorbance showed no difference between samples. (D) Lysis profile for non-recurrent and recurrent VTE plasma clots measured at
340 nm. (E, F) Time to half-lysis (E) and average lysis rate (normalized change per second) (F) for plasma clots showed no difference between
samples. *P < 0.05.
Table 3 Turbidity and lysis for venous thromboembolism (VTE) plasma clots
VTE patients (n = 44) Recurrent VTE (n = 11) Non-recurrent VTE (n = 33) P-value
Lag time (s) 190.1  22.5 183.1  14.6 192.5  24.3 0.054
Time to maximum absorbance (min) 108  19 101  20 110  18 0.170
Average rate of clotting (change OD s–1) 0.12  0.04 0.12  0.03 0.12  0.04 0.730
Maximum absorbance (k = 340 nm) 0.51  0.12 0.44  0.14 0.52  0.11 0.046
Time to half-lysis (min) 45.7  18.1 43.5  12.7 46.5  19.8 0.642
Average rate of lysis (DOD s–1) 0.031  0.012 0.027  0.010 0.033  0.012 0.122
Values are given as mean  standard deviation. P-values were obtained with Student’s t-test.
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compared with rVTE patients. In contrast, there were no
significant differences in the mechanical properties (Gʹ or
G″) of clots made from purified fibrinogen. As no differ-
ence in elastic modulus was observed for clots prepared
from purified fibrinogen, the effects on clot mechanics in
rVTE patients are therefore probably not caused by struc-
tural changes in fibrinogen itself. These data support the
view that analysis of plasma clot features may provide
more clinically relevant information on the association
between clot phenotype and thromboembolic risk than
purified fibrinogen samples.
Few studies have investigated the viscoelastic proper-
ties of clots made from VTE patients. Martinez et al.
showed that, although there was accelerated establish-
ment of viscoelastic properties for acute PE patients ver-
sus acute DVT patients, the final elastic and viscous
properties were similar between the two groups [10]. It
should be noted that clots were not separated into rVTE
or nrVTE in that particular study. In addition, these
experiments were performed with a bulk rheometer,
which, as noted above, is less sensitive to small changes
in viscoelastic properties than microrheometry. The cur-
rent study expands previous findings by showing altered
viscoelastic clot characteristics in plasma from patients
with rVTE versus plasma from patients with nrVTE,
which highlights a potential use for fibrin viscoelastic
assessment in the prediction of rVTE.
Interestingly, previous work has shown that clot struc-
tures for samples from patients with recurrent and non-
recurrent PE were different, with recurrent PE clots being
more densely packed and less porous than non-recurrent
PE clots, although these clots were made with purified fib-
rinogen [24]. Similarly, it was shown that recurrent DVT
was associated with less permeable clots than non-recur-
rent DVT, suggesting that these clots are less porous [25].
In the current study, turbidity experiments showed that
there was a higher maximum absorbance for nrVTE
plasma samples. This could indicate that nrVTE plasma
samples produce more densely packed clots. However, this
could not be confirmed by analysis of clot architecture with
laser scanning confocal microscopy, which showed no dif-
ference in fiber density between the groups.
Prolonged lysis times have been implicated as a risk fac-
tor for venous thrombosis [26]. Some evidence suggests
that increased lysis times predict recurrence of VTE in
women but not in men [9], whereas other studies have sug-
gested that increased lysis times predict the initial risk of
venous thrombosis, but not the recurrence [26]. Here, we
found no difference in lysis time or rate of lysis between
rVTE and nrVTE patient plasma samples, which is consis-
tent with the absence of major changes in clot architecture
in plasma clots from patients with rVTE.
Lower clot elastic moduli several months after the last
VTE event may suggest that such properties enhance
recurrence. It remains to be established whether a reduced
elastic modulus of fibrin clots does enhance thrombus for-
mation or embolization in prospective studies of patients
with VTE.
As differences in viscoelastic properties were observed
in plasma samples, but not in purified fibrinogen sam-
ples, we also analyzed typical markers for VTE recur-
rence (age, sex, body mass index, unprovoked VTE,
and family history of VTE), although no significant dif-
ferences were found. We observed no significant differ-
ence in either average fiber radius or number of
protofibrils per fibrin fiber between plasma clots made
from rVTE samples and those made from nrVTE sam-
ples. Similarly, clots made from purified fibrin showed
no significant difference in either average fiber radius or
average number of protofibrils between rVTE samples
and nrVTE samples. It should be noted that the num-
ber of samples was limited and that the variation in
these measurements was large. Finally, no changes in
FXIII levels were observed, indicating that the change
in elastic modulus for rVTE samples was not caused by
changes in fibrin cross-linking.
Predicting VTE recurrence from clot viscoelastic prop-
erties would allow for personalization of treatment for
each individual patient. This might suggest that there
could be multiple groups in the nrVTE samples, with one
group having a lower clot elastic moduli than another.
No significant grouping was observed within the nrVTE
plasma samples, although there do seem to be specific
samples with lower values than the average. Future
prospective studies of clot mechanical characteristics in
nrVTE patients, testing for recurrence, could help to
determine whether clot elastic modulus can be used as a
predictor for VTE recurrence.
In summary, we found a significantly reduced elastic
modulus in plasma clots from patients with rVTE. The
reduced elastic modulus was not associated with major
changes in the elastic modulus of clots made from puri-
fied fibrinogen, plasma fibrinogen levels, plasma clot
architecture, or plasma FXIII activity levels, suggesting
that other plasma factors are at play in determining clot
mechanics in patients with rVTE. Future studies in larger
patient populations are required to corroborate these
findings, elucidate the plasma-based mechanisms involved,
and test the prognostic value of clot elastic modulus in
predicting VTE recurrence.
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